nach oben

Drugs & Aging

Erschienen in:

01.11.2003 | Review Article

Aspirin for the Prevention of Cardiovascular Events in the Elderly

verfasst von: Dr Isabelle Mahé, Alain Leizorovicz, Charles Caulin, Jean-François Bergmann

Erschienen in: Drugs & Aging | Ausgabe 13/2003

Einloggen, um Zugang zu erhalten

Abstract

Aspirin (acetylsalicylic acid), the most widely used antiplatelet drug, is clinically effective for the prevention of vascular ischaemic events. Very few primary or secondary prevention trials address the benefit-risk ratio of aspirin in the elderly.

In secondary prevention, it is generally accepted that the beneficial effect of aspirin in the general patient population, demonstrated by randomised controlled trials, can be extrapolated to the elderly. Elderly patients are at relatively high risk for the development of vascular disease and might also be expected to derive substantial benefit from regular aspirin administration. However, there is no consensus about the definition of elderly and no specific prospective trial conducted in elderly subjects is available. Retrospective studies in the elderly found that the benefit provided by aspirin in older patients was similar or increased compared with younger individuals.

In primary prevention, the potential benefit of antiplatelet agents must be balanced against the risk of bleeding, which is higher in older patients. The risk-benefit trade-off from the use of low-dose aspirin in the elderly is not yet established and caution should be exercised when using aspirin in primary prevention.

In conclusion, aspirin should only be given for primary and secondary prevention in the elderly after a comprehensive evaluation of an individual patient’s thrombotic and haemorrhagic risk has been conducted.

Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: The Cardiovascular Health Study. JAMA 1998; 279: 585–92PubMedCrossRef

Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452–63PubMed

Hirsch J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanisms of action, clinical effectiveness and optimal therapeutic range. Chest 2001; 119: 8S–21SCrossRef

Calverley DC. Antiplatelet therapy in the elderly: aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. Clin Geriatr Med 2001; 17: 31–48PubMedCrossRef

Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationship among dose, effectiveness and side effects. Chest 2001; 119: 39S–63SPubMedCrossRef

Murray CJL, Lopez AD. Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436–42PubMedCrossRef

Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333–9PubMedCrossRef

Aronow WS, Ahn C. Prevalence of coexistence of coronary disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol 1994; 74: 64–5PubMedCrossRef

Cupples LA, D’Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurement. In: Kannel WB, Wolf PA, Garrison RJ, editors. Framingham Study; 30 years follow-up. National Institutes of Heath Publication No. 82-2703. Springfield (VA): Department of Commerce, National Technical Information Service, 1987

10.

Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995; 46: 715–8PubMedCrossRef

11.

van Gorp EC, Brandjes DP, ten Cate JW. Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. Drugs Aging 1998; 13: 145–57PubMedCrossRef

12.

Nurmohamed MT, Buller HR, ten Cate JW. Physiological changes due to age: implications for the prevention and treatment of thrombosis in older patients. Drugs Aging 1994; 5: 20–33PubMedCrossRef

13.

Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery diseases and acute coronary syndromes. N Engl J Med 1992; 326: 310–8PubMedCrossRef

14.

Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331: 468–9PubMedCrossRef

15.

Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9PubMedCrossRef

16.

Stampfer MJ, Jakubowski JA, Deykin D, et al. Effect of alternate-day regular and enteric-coated aspirin on platelet aggreagation, bleeding time, and thromboxane A2 levels in bleeding-time blood. Am J Med 1986; 81: 400–4PubMedCrossRef

17.

Patrono C, Ciabattonni G, Patrignani P, et al. Clinical pharmacology of platelet cyclo-oxygenase inhibition. Circulation 1985; 72: 1177–84PubMedCrossRef

18.

Patrono C. Aspirin as an antiplatelet agent. N Engl J Med 1994; 330: 1287–94PubMedCrossRef

19.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRef

20.

Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRef

21.

Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197–202PubMedCrossRef

22.

Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomised trials. Arch Intern Med 1997; 157: 1237–40CrossRef

23.

Cleland JG. No reduction in cardiovascular risk with NSAIDS-including aspirin. Lancet 2002; 359: 92–3PubMedCrossRef

24.

Cleland JG. Preventing atherosclerotic events with aspirin. BMJ 2002; 324: 103–5PubMedCrossRef

25.

Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–5PubMedCrossRef

26.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–60

27.

Krumholz HM, Radfoed MJ, Eilerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation 1995; 92: 2841–7PubMedCrossRef

28.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39CrossRef

29.

Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001, 206S

30.

Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91

31.

Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527–39CrossRef

32.

The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273–37CrossRef

33.

Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 1999; 131: 492–501

34.

European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62

35.

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62PubMedCrossRef

36.

Kjeldsen SE, Kolloch RE, Leonetti, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000; 18: 629–42PubMedCrossRef

37.

Steering Committee of the Physicians Study Research Group. Final report on the aspirin component of the ongoing physicians study. N Engl J Med 1989; 321: 129–35CrossRef

38.

The Medical Research Council’s. General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233–41CrossRef

39.

Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–7PubMedCrossRef

40.

Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001 13; 357: 89–95

41.

Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med 2002; 136: 161–72PubMed

42.

Silagy CA, McNeil JJ, Donnan GA, et al. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly (Prevention with low-dose aspirin of cardiovascular disease in the elderly). J Am Geriatr Soc 1994; 42: 643–7PubMed

43.

Buring JE, Hennekens CH. The Women’s Health Study: summary of the study design. J Myocardial Ischemia 1992; 4: 30–9

44.

Silagy CA, McNeil JJ, Donnan GA. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84–9PubMedCrossRef

45.

Silagy CA, McNeil JJ, Bulpitt CJ, et al. Rationale for a primary prevention study of low-dose aspirin to prevent cardiovascular disease in elderly. J Am Geriatr Soc 1991; 39: 484–91PubMed

46.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–46CrossRef

47.

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295–302

48.

Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S–75SPubMedCrossRef

49.

Nascitz JE, Yeshurun D, Odeh M, et al. Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol 1990; 85: 408–11

50.

UK TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 296: 316–20CrossRef

51.

Boysen G, Soelberg-Sorensen P, Juhler M. Danish very-low dose aspirin after carotid endarteriectomy trial. Stroke 1988; 19: 1211–5PubMedCrossRef

52.

de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001; 1: 1–10PubMedCrossRef

53.

Faulkner G, Prichard P, Somerville K, et al. Aspirin and bleeding peptic ulcers in the elderly. BMJ 1988; 297: 1311–3PubMedCrossRef

54.

Quilliam BJ, Lapane KL, Eaton CB, et al. Effect of antiplatelet and anticoagulant agents on risk of hospitalization for bleeding among a population of elderly nursing home stroke survivors. Stroke 2001; 32: 2299–304PubMedCrossRef

55.

He J, Whelton PK, Vu B, et al. Aspirin and risk of haemorrhagic stroke: a meta-analysis of randomised controlled trials. JAMA 1998; 280: 1930–5PubMedCrossRef

56.

Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101: 1097–101PubMedCrossRef

57.

Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316: 1430–4PubMedCrossRef

58.

MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease: early safety and efficacy experience. Eur Heart J 1999; 20: 725–41CrossRef

59.

Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA guideline update for the management of patients with unstable angina and chronic stable angina: summary article: a report of the American College of Cardiology/American Heart Association task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation 2003; 107: 149–58PubMedCrossRef

60.

Braunwald E, Antman E, Beasley JW, et al. AHA Guideline update for the management of patients with unstable angina and non-st-segment elevation myocardial infarction, 2002: summary article: a report of the American College of Cardiology/American Heart Association task Force on Pratcice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002; 106: 1893–900PubMedCrossRef

61.

Aronow WS. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease. Drugs Aging 1999; 15: 91–101PubMedCrossRef

62.

Aronow WS, Frishman WH, Cheng-Lai L. Cardiovascular drug therapy in the elderly. Heart Dis 2000; 2: 151–67PubMed

63.

Aronow WS. Drug treatment of elderly patients with acute myocardial infarction: practical recommendations. Drugs Aging 2001; 18: 807–18PubMedCrossRef

64.

Ramsay LE, Sanmuganathan PS, Wallis EJ, et al. Aspirin for primary prevention: treatment policy should be based on all trial evidence, not subgroup analysis [letter]. BMJ 2000; 321: 1472PubMedCrossRef

65.

Lauer M. Aspirin for primary prevention of coronary events. N Engl J Med 2002; 346: 1468–74PubMedCrossRef

66.

Sox HC. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 157–60

67.

Cairns JA, Théroux P, Lewis HD, et al. Antithrombotic agents in coronary heart disease. Chest 2001; 119: 228S–52SPubMedCrossRef

68.

Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. Circulation 2002; 106: 388–91PubMedCrossRef

69.

US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation ans rationale. Ann Intern Med 2002; 136: 157–60

Titel: Aspirin for the Prevention of Cardiovascular Events in the Elderly
verfasst von: Dr Isabelle Mahé
Alain Leizorovicz
Charles Caulin
Jean-François Bergmann
Publikationsdatum: 01.11.2003
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 13/2003
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200320130-00004

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen